Cure My Disease

Don't miss your cure!

 Log in / Sign up

Catheter study for lung blood clots pulled before it started

NCT ID NCT06975969

Disease control Sponsor: Liquet Medical Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test a special catheter that delivers clot-dissolving medicine directly into the lungs of people with blood clots. The trial was withdrawn before enrolling any participants, so no results are available. It would have included adults aged 18 to 80 with submassive pulmonary embolism.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Started

Sep 2025

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients age 18 - 80 years old who present with symptoms requiring intervention with delivery of physician-specified thrombolytics to the pulmonary vasculature, including patients who present with submassive pulmonary embolism (PE), who receive treatment using the Versus™ Catheter.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients 18 - 80 years, inclusive * Patients who present with submassive pulmonary embolism (PE) * Patients requiring thrombolytic intervention to the pulmonary vasculature * Physician decision to use the Versus™ Catheter during the treatment of the patient Exclusion Criteria: * Concurrent treatment with thrombectomy * Concurrent treatment with a catheter-directed thrombolysis device that is NOT the Versus™ Catheter * Massive pulmonary embolism (PE) * Active bleeding disorder1 * Recent cerebrovascular accident or transient ischemic attack1 * Recent neurosurgery1 * Recent intracranial trauma1 * Absolute contraindication to anticoagulation1 * BMI \> 45kg/m2 * In the opinion of the investigator, the participant is not a suitable candidate for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood clots are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Embolism and Thrombosis lung disorder pulmonary embolism thrombotic disease vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood clots Cardiovascular diseases Embolism thrombosis Lung diseases Vascular disease

Contacts and locations

Locations

  • University of Virginia Medical Center

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.